Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) Net Margin (2021 - 2025)

Mirum Pharmaceuticals has reported Net Margin over the past 5 years, most recently at 3.85% for Q4 2025.

  • Quarterly results put Net Margin at 3.85% for Q4 2025, up 2008.0% from a year ago — trailing twelve months through Dec 2025 was 4.48% (up 2162.0% YoY), and the annual figure for FY2025 was 4.48%, up 2162.0%.
  • Net Margin for Q4 2025 was 3.85% at Mirum Pharmaceuticals, down from 2.18% in the prior quarter.
  • Over the last five years, Net Margin for MIRM hit a ceiling of 1825.37% in Q4 2021 and a floor of 942.16% in Q3 2021.
  • Median Net Margin over the past 5 years was 49.42% (2023), compared with a mean of 41.91%.
  • Peak annual rise in Net Margin hit 75203bps in 2022, while the deepest fall reached -195592bps in 2022.
  • Mirum Pharmaceuticals' Net Margin stood at 1825.37% in 2021, then tumbled by -107bps to 130.55% in 2022, then soared by 61bps to 51.27% in 2023, then skyrocketed by 53bps to 23.93% in 2024, then surged by 84bps to 3.85% in 2025.
  • The last three reported values for Net Margin were 3.85% (Q4 2025), 2.18% (Q3 2025), and 4.59% (Q2 2025) per Business Quant data.